Russo Partners’ Post

Great to be featured in this report on the #MedTech sector published by RSM Australia. Their expertise navigating complex #globalmarkets has been integral to our #southeastasia expansion. #pharmaceuticals #businessdevelopment

Dr. Terri Gaskell, CTO of Rinri Therapeutics, shares her insights on developing and manufacturing a PSC therapeutic at IMAPAC Biomanufacturing 5.0 conference today in London. Her advice? Begin with the end in mind. Don't just focus on what is acceptable in a First-In-Human (FIH) trial, but consider what will likely change to generate a commercial product. Dr. Gaskell emphasizes the importance of collecting everything while developing your manufacturing process. This will facilitate retrospective analysis and help you identify areas for improvement. Additionally, it's crucial to know the sensitivity, robustness, and limitations of your tools. Rely on them only as much as justified. Bank sufficient material to validate your assays if justified in risk assessment. Remember, developing a successful commercial product requires thoughtful planning and attention to detail. Thank you, Terri, for sharing your valuable insights. #productdevelopment #manufacturingprocess #commercialproduct #biotech #advancedtherapies #PSC

We’re delighted to share insights from our CEO, Dr. Ross Burn, on our latest acquisition of Reach Separations: "We are excited to welcome Reach Separations into the CatSci Ltd Group. The need for solving complex analytical problems while meeting the ever-evolving regulatory demands is growing alongside the development of new modalities, such as oligonucleotides, TACs, and glues. Joining forces with Reach gives our customers access to end-to-end coverage of the analytical development lifecycle, taking them from discovery through to GMP manufacture, and ultimately enabling them to help patients in need." This acquisition enhances our ability to deliver end-to-end analytical support from discovery through launch. Together with Reach, we are committed to better serving our customers and accelerating the development of life-changing therapeutics. Discover more here: https://lnkd.in/ebprErGt #ExcellenceInMedicinesDevelopment #ProudToBeCatSci #DrugDevelopment #MedicinesDevelopment

This is really interesting! Nimbus Therapeutics has made waves with this setup, which started with Bruce Booth from Atlas Venture. It’s impressive how this model has led to deals worth over $7.1B, returned $4.1B to investors, and pushed three programs into clinical trials. It shows that while the business model is important, solid science and data are key. #biotech, #pharma, #businessmodel

Great to see L.E.K. Consulting's report about the 'hub-and-spoke' business model. Nimbus Therapeutics' played a pioneering role in advancing this model (also referenced as the LLC/sub-co model) in biopharma, a structure notably discussed by our founding investor & Chairman, Bruce Booth, from Atlas Venture with great legal counsel from Goodwin. Early blogs about Nimbus' structure from Bruce in 2011 (https://rb.gy/4tk0p0) and 2013 (https://rb.gy/fzo2dp). This innovative approach has enabled us to execute deals with exceptional partners with terms over $7.1B in value, return $4.1B to investors (to-date), and most importantly, advance three programs into the clinic. By leveraging centralized leadership and specialized subsidiaries, we've enhanced focus, operational efficiency, and risk mitigation, driving significant progress in our mission to bring transformative medicines to patients. While all this is great for the business and legal savants, at the end of the day, the business structure can only work if the scientific rationale and supportive data are there - the fundamentals that drive our industry. For more insights of the Hub-and-Spoke model, check out this report by L.E.K. Consulting: https://lnkd.in/e34nEmaU #Biopharma #Innovation #HubAndSpoke #NimbusTherapeutics #PatientCare #LifeSciences

"You need to have something pretty special to attract people to your organization" TScan Therapeutics are investing heavily in their L&D programs and are definitely leading by example. The question is how long will it take the rest of the industry to catch up and will we see it have a direct impact on the retention rate among BioPharma firms? To read the full report, click on the link in the comments 👇

One more trial failure of #Keytruda.  But the biggest learning is trial failures are common in drug development and #Merck is not shying away from testing different combinations to improve OS and PFS.  Even after becoming the SoC for #lungcancer for different types and lines, changing the treatment landscape, Merck is not stopping and its investment in assets is key for success.  It's been a decade since the launch of #Keytruda and yet there are so many trials (~1,600 trials), that show how one can make a product commercially successfully. Still 3-5 out of 10 press releases are on Keytruda and that shows commitment. https://lnkd.in/gRCzED4i

As pharma companies increasingly try to incorporate Digital therapeutics (DTx) into their strategies, they face challenges in navigating regulatory uncertainty and slow adoption rates. Our latest article explores the complex world of digital therapeutics and presents Ipsos' 5-stage framework for developing resilient and scalable DTx businesses. Download the full article to discover key insights and strategies for success in this rapidly evolving industry. https://lnkd.in/dwG9NNt5 #DigitalTherapeutics #DTx #HealthcareInnovation #PharmaStrategy

Recently, Alex Pasteur, Partner at F-Prime Capital, had the opportunity to sit down with Dylan Neel at Biomarker to discuss his career journey, lessons learned as a life science investor, and what excites him about the future of the radiopharmaceutical industry including our investment in ARTBIO. Link in comments to learn more. #biotech #radiopharmaceuticals #nuclearmedicine

There is still time to join this week's virtual discussion analysing the #pharma industry's fastest growing and biggest selling drug brands. Register today! https://lnkd.in/dqbJu-9P Sponsored by Cencora Not sure you can join live? We've got you covered! Register and you will be able to view the event on-demand once it concludes. #biopharma #drugdevelopment #marketanalysis #pharmaceuticals